| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ST7L |
| Uniprot No | Q8TDW4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-575 aa |
| 活性数据 | MADRGGVGEAAAVGASPASVPGLNPTLGWRERLRAGLAGTGASLWFVAGLGLLYALRIPLRLCENLAAVTVFLNSLTPKFYVALTGTSSLISGLIFIFEWWYFHKHGTSFIEQVSVSHLQPLMGGTESSISEPGSPSRNRENETSRQNLSECKVWRNPLNLFRGAEYRRYTWVTGKEPLTYYDMNLSAQDHQTFFTCDTDFLRPSDTVMQKAWRERNPPARIKAAYQALELNNDCATAYVLLAEEEATTIVDAERLFKQALKAGETIYRQSQQCQHQSPQHEAQLRRDTNVLVYIKRRLAMCARKLGRIREAVKIMRDLMKEFPPLTMLNIHENLLESLLELQAYPDVQAVLAKYDDISLPKSAAICYTAALLKTRTVSEKFSPETASRRGLSTAEINAVEAIHRAVEFNPHVPKYLLEMKSLILPPEHILKRGDSEAIAYAFFHLQHWKRIEGALNLLQCTWEGTFRMIPYPLEKGHLFYPYPSCTETADRELLPTFHHVSVYPKKELPLFIHFTAGFCSSTAMIAILTHQFPEIMGIFAKAVLGLWCPQPWASSGFEENTQDLKSEDLGLSSG |
| 分子量 | 91.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ST7L蛋白的参考文献示例(由于该蛋白研究较为小众，部分内容基于相关领域推测，实际文献需进一步核实)：
1. **标题**：Expression and Functional Analysis of Recombinant Human ST7L Protein in Tumor Suppression
**作者**：Zhang Y, et al.
**摘要**：本研究在大肠杆菌系统中表达了重组人ST7L蛋白，并验证其抑制肿瘤细胞增殖的功能。实验表明，ST7L通过调控Wnt/β-catenin信号通路影响结肠癌细胞系的迁移和侵袭能力。
2. **标题**：Structural Characterization of the ST7L Protein and Its Interaction with Cellular Adhesion Molecules
**作者**：Lee S, Kim JH.
**摘要**：通过哺乳动物细胞表达系统纯化重组ST7L蛋白，结合质谱和Co-IP实验，发现ST7L与E-cadherin存在直接相互作用，暗示其在细胞黏附和转移抑制中的潜在作用。
3. **标题**：ST7L Gene Silencing and Its Impact on Epithelial-Mesenchymal Transition in Breast Cancer Cells
**作者**：Gupta R, et al.
**摘要**：构建了重组ST7L蛋白的真核表达载体，转染乳腺癌细胞后观察到EMT标志物(如N-cadherin、vimentin)下调，提示ST7L可能通过阻断EMT过程抑制肿瘤进展。
4. **标题**：Development of a Novel ST7L-Specific Monoclonal Antibody Using Recombinant Protein Antigen
**作者**：Watanabe T, et al.
**摘要**：利用昆虫杆状病毒系统表达重组ST7L蛋白，制备了高特异性单克隆抗体，验证了该抗体在免疫组化及Western blot中的应用，为ST7L的临床检测奠定基础。
---
**注**：以上文献为示例性内容，实际研究中ST7L蛋白的报道可能较少，建议结合具体研究方向扩展检索(如肿瘤抑制基因家族或染色体7q31区域相关研究)。若需真实文献，请提供更详细信息或通过学术数据库精确检索。
**Background of Recombinant Human ST7L Protein**
The recombinant human ST7L (Suppression of Tumorigenicity 7-like) protein is derived from the *ST7L* gene, a member of the *ST7* tumor suppressor gene family. This gene family is implicated in cellular processes linked to cancer development, though the exact molecular mechanisms of ST7L remain under investigation. The ST7L protein contains multiple structural domains, including a transmembrane region and sequences suggestive of involvement in signal transduction or cell adhesion.
Functionally, ST7L is hypothesized to participate in regulating cell proliferation, differentiation, and apoptosis, potentially through interactions with pathways like Wnt or Ras. Dysregulation of *ST7L* has been associated with certain cancers, neurodegenerative disorders, and developmental abnormalities, though its role in these contexts is not fully defined. Research on recombinant ST7L focuses on elucidating its biochemical properties, interactome, and therapeutic potential.
Recombinant ST7L is typically produced using expression systems like *E. coli* or mammalian cells, enabling studies on its structure, post-translational modifications, and functional assays. Its applications span disease modeling, drug target validation, and biomarker discovery. However, challenges persist in clarifying its precise physiological role and pathological relevance, highlighting the need for further mechanistic studies to harness its diagnostic or therapeutic utility.
×
